17β hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma

Gynecologic Oncology

Volumn 127, Issue 3, 2012, Pages 587-594

  Szajnik, Marta ^a,d,f   Szczepanski, Miroslaw J ^a,d   Elishaev, Esther ^c   Visus, Carmen ^a   Lenzner, Diana ^b   Zabel, MacIej ^d,e   Glura, Marta ^d   Deleo, Albert B ^a   Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

^f MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

HSD17B12; HSD17B12 silencing; Ovarian carcinoma; Prognosis

Indexed keywords

17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 12; ARACHIDONIC ACID; ESTRADIOL; LIPOCORTIN 5; SMALL INTERFERING RNA; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN BINDING;

17-HYDROXYSTEROID DEHYDROGENASES; APOPTOSIS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; PROGNOSIS; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 84868535825     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.08.010     Document Type: Article

References (28)

1. A. Jemal, A. Thomas, T. Murray, and M. Thun Cancer statistics, 2002 CA Cancer J Clin 52 1 2002 23 47
2. J. Mrochem, K. Sadowski, R. Deja, A. Walaszek-Gruszka, A. Wojcieszek, and Z. Kolosza Evaluation of selected serum protein markers as early detectors of ovarian cancer Ginekol Pol 79 4 2008 271 275
3. H. Naora Developmental patterning in the wrong context: the paradox of epithelial ovarian cancers Cell Cycle 4 8 2005 1033 1035
4. P.A. Wood, K. Bove, S. You, A. Chambers, and W.J. Hrushesky Cancer growth and spread are saltatory and phase-locked to the reproductive cycle through mediators of angiogenesis Mol Cancer Ther 4 7 2005 1065 1075
5. S.A. Vantyghem, C.O. Postenka, and A.F. Chambers Estrous cycle influences organ-specific metastasis of B16F10 melanoma cells Cancer Res 63 16 2003 4763 4765
6. V. Luu-The, A. Belanger, and F. Labrie Androgen biosynthetic pathways in the human prostate Best Pract Res Clin Endocrinol Metab 22 2 2008 207 221
7. P. Lukacik, K.L. Kavanagh, and U. Oppermann Structure and function of human 17beta-hydroxysteroid dehydrogenases Mol Cell Endocrinol 248 1-2 2006 61 71
8. F. Labrie, V. Luu-The, S.X. Lin, C. Labrie, J. Simard, and R. Breton The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology Steroids 62 1 1997 148 158
9. X. Wu, P. Lukacik, K.L. Kavanagh, and V. Oppermann SDR-type human hydroxysteroid dehydrogenases involved in steroid hormone activation Mol Cell Endocrinol 265-266 2007 71 76
10. R. Mindnich, G. Moller, and J. Adamski The role of 17 beta-hydroxysteroid dehydrogenases Mol Cell Endocrinol 218 1-2 2004 7 20
11. T. Suzuki, Y. Miki, H. Nakamura, T. Moriya, K. Ito, and N. Ohuchi Sex steroid-producing enzymes in human breast cancer Endocr Relat Cancer 12 4 2005 701 720
12. H. Sasano, T. Suzuki, H. Niikura, K. Kaga, S. Sato, and A. Yajima 17 beta-hydroxysteroid dehydrogenase in common epithelial ovarian tumors Mod Pathol 9 4 1996 386 391
13. H. Tokunaga, J. Akahira, T. Suzuki, T. Moriya, H. Sasano, and K. Ito Ovarian epithelial carcinoma with estrogen-producing stroma Pathol Int 57 5 2007 285 290
14. S. Nagasaki, T. Suzuki, Y. Miki, J. Akahira, K. Kitada, and T. Ishida 17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis Cancer Res 69 4 2009 1392 1399
15. D.S. Rickman, R. Millon, A. DeReynies, E. Thomas, C. Wasylyk, and D. Muller Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays Oncogene 27 51 2008 6607 6622
16. D. Song, G. Liu, V. Luu-The, D. Zhao, L. Wang, and H. Zhang Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study. J Steroid Biochem Mol Biol 101 2-3 2006 136 144
17. A.R. Folsom, J.P. Anderson, and J.A. Ross Estrogen replacement therapy and ovarian cancer Epidemiology 15 1 2004 100 104
18. J.V. Lacey Jr., P.J. Mink, J.H. Lubin, M.E. Sherman, R. Troisi, and P. Hartge Menopausal hormone replacement therapy and risk of ovarian cancer JAMA 288 3 2002 334 341
19. S.M. Hyder, Z. Nowaz, C. Chiappetta, and G.M. Stancel Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor Cancer Res 60 12 2000 3183 3190
20. G.N. Armaiz-Pena, L.S. Mangala, W.A. Spannuth, Y.G. Lin, N.B. Jennings, and A.M. Nick Estrous cycle modulates ovarian carcinoma growth Clin Cancer Res 15 9 2009 2971 2978
21. N. Sakurai, Y. Miki, T. Suzuki, K. Watanabe, T. Narita, and K. Ando Systemic distribution and tissue localizations of human 17beta-hydroxysteroid dehydrogenase type 12 J Steroid Biochem Mol Biol 99 4-5 2006 174 181
22. R.C. Hendrickson, V.R. Cicinnati, A. Albers, G. Dworacki, A. Gambotto, and O. Pagliano Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide Cancer Immunol Immunother. 59 1 2010 113 124
23. S.J. Martin, C.P. Reutelingsperger, A.J. McGahon, J.A. Rader, R.C. van Schie, and D.M. LaFace Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl J Exp Med 182 5 1995 1545 1556
24. M.J. Szczepanski, M. Czystowska, M. Szajnik, M. Harasymczuk, M. Boyiadzis, and A. Kruk-Zagajewska Triggering of toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack Cancer Res 69 7 2009 3105 3113
25. M. Szajnik, M.J. Szczepanski, M. Czystowska, E. Elishaev, M. Manda Pathil, and E. Nowak-Markwitz TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer Oncogene 28 49 2009 4353 4363
26. R. Ali-Fehmi, A. Semaan, S. Sethi, H. Arabi, S. Bandyopadhyay, and Y.R. Hussein Molecular typing of epithelial ovarian carcinomas using inflammatory markers Cancer 117 2 2011 301 309
27. C. Visus, D. Ito, R. Dhir, M.J. Szczepanski, Y.J. Chang, and J.J. Latimer Identification of hydroxysteroid (17beta) dehydrogenase type 12 (HSD17B12) as a CD8(+) T-cell-defined human tumor antigen of human carcinomas Cancer Immunol Immunother 60 7 2011 919 929
28. A. Jansson 17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer J Steroid Biochem Mol Biol 114 1-2 2009 64 67